Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURITY: Phthalates and Renal Function in T2D (SGLT2 Subprotocol)
NCT04242758Phase 4Unknown
- Sponsor
- University of Pisa
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Pisa. Primary endpoint: Urinary Phthalates concentration at 3 months. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04242758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242758.